AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients

AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimers disease.